AASLD 2012: Brivanib Fails to Match Sorafenib for Liver Cancer, but Tivatinib Looks Promising
- Details
- Category: Liver Cancer/HCC
- Published on Friday, 30 November 2012 00:00
- Written by Liz Highleyman
The investigational cancer drug brivanib did not significantly increase overall survival for patients with hepatocellular carcinoma compared with existing standard therapy, researchers reported at the 63rd Annual Meeting of the American Association for the Study of Liver Diseases (AASLD 2012) this month in Boston. But another drug, tivatinib, did appear beneficial for a subset of patients. 
AASLD 2012: Telaprevir and VX-222 Pair Well in Interferon-free Regimens, VX-135 on the Horizon
- Details
- Category: HCV Treatment
- Published on Wednesday, 28 November 2012 00:00
- Written by Liz Highleyman
An all-oral regimen of telaprevir, VX-222, and ribavirin for 12 weeks was generally well-tolerated and produced sustained response in approximately 70% of previously untreated chronic hepatitis C patients, including those with hard-to-treat HCV subtype 1a, according to study findings presented at the American Association for the Study of Liver Diseases Liver Meeting (AASLD 2012) this month in Boston.
AASLD 2012: When Are HCV Direct-Acting Antivirals Needed, Who Should Be Prioritized?
- Details
- Category: Liver Cancer/HCC
- Published on Monday, 26 November 2012 00:00
- Written by Rob Camp
When resources for hepatitis C treatment with new direct-acting antivirals are limited, findings from the U.S. suggest that previously untreated people with low HCV viral loads may stand a good chance of achieving sustained virological response without adding telaprevir or boceprevir to pegylated interferon and ribavirin, researchers reported at the American Association for the Study of Liver Diseases Liver Meeting (AASLD 2012) this month in Boston. A related study suggests that younger hepatitis C patients with advanced liver disease should be prioritized for treatment with the new drugs. 
AASLD 2012: Avatrombopag Reduces Bleeding Risk for Liver Disease Patients Undergoing Surgery
- Details
- Category: HCV Treatment
- Published on Monday, 26 November 2012 00:00
- Written by Liz Highleyman
The experimental thrombopoietin receptor agonist avatrombopag (E5501) effectively increased platelet counts in patients with chronic liver disease enough to enable them to safely undergo scheduled surgeries, according to data presented at the American Association for the Study of Liver Diseases Liver Meeting (AASLD 2012) this month in Boston. 
AASLD 2012: Nucleoside Analogs Reduce Hepatitis B Liver Cancer Risk, Cirrhosis Remains a Concern
- Details
- Category: HBV Treatment
- Published on Sunday, 25 November 2012 00:00
- Written by Liz Highleyman
Treatment of chronic hepatitis B with nucleoside/nucleotide analogs including lamivudine (Epivir-HBV) and entecavir (Baraclude) can reduce the risk of developing hepatocellular carcinoma, including cancer recurrence after successful resection, according to studies presented at the recent American Association for the Study of Liver Diseases Liver Meeting (AASLD 2012) and published in the Journal of the American Medical Association. 
More Articles...
- AASLD 2012: Telaprevir Twice-daily Works as Well as Every 8 Hours, Safe for Hep C Patients with Cirrhosis
- AASLD 2012: Simeprevir Safe and Effective for Hepatitis C Patients With Cirrhosis
- AASLD 2012: Interferon-free Faldaprevir + BI 207127 Safe and Effective for Hepatitis C Patients with Cirrhosis
- AASLD 2012: Sofosbuvir + GS-5885 + Ribavirin Shows High Early Response Rates for Genotype 1 HCV
Web Design and Development by